Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages 1175-1181

  Chen, Christine I ^a   Bergsagel, P Leif ^a   Paul, Harminder ^a   Xu, Wei ^a   Lau, Anthea ^a   Dave, Nimisha ^a   Kukreti, Vishal ^a   Wei, Ellen ^a   Leung Hagesteijn, Chungyee ^a   Li, Zhi Hua ^a   Brandwein, Joseph ^a   Pantoja, Mariela ^a   Johnston, James ^a   Gibson, Spencer ^a   Hernandez, Tiffany ^a   Spaner, David ^a   Trudel, Suzanne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; LENALIDOMIDE; PREDNISONE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPERKALEMIA; HYPERNATREMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEG EDEMA; LUNG INFECTION; LYMPHOCYTOSIS; MACULOPAPULAR RASH; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NEUTROPENIA; PERIPHERAL LYMPHOCYTE; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RECURRENT INFECTION; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SINUS INFECTION; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR FLARE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; WOUND INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REMISSION INDUCTION; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952769640     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.8133     Document Type: Article

References (34)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomized, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
2. Dredge K, Horsfall R, Robinson S, et al: Orally administered lenalidomide is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56-63, 2005 (Pubitemid 40410468)
3. Schafer P, Gandhi A, Loveland M, et al: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharm Exp Therapeutics 305:1222-1232, 2003 (Pubitemid 36618002)
4. Corral L, Haslett P, Muller F, et al: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide anlaogues that are potent inhibitors of TNF-alpha. J Immunol 163:380-386, 1993
5. Andritsos L, Johnson AJ, Lozanski G, et al: C: Higher doses of lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26:2519-2525, 2008
6. Lapalombella R, Andritsos L, Liu Q, et al: Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B Cells through a PI3-kinase dependent pathway. Blood 115:2619-2629, 2010
7. James D, Betty M, Mosadeghi R, et al: Lenalidomide abrogates the protective influence of nurse-like cells on primary chronic lymphocytic leukemia cells in vitro. Blood 110:916a, 2007 (abstr 3116)
8. Ramsay A, Johnson A, Lee A, et al: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immuomodulating drug. J Clin Invest 118:2427-2437, 2008 (Pubitemid 351949771)
9. Chanan-Khan A, Killer K, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006 (Pubitemid 46623164)
10. Ferrajoli A, Lee B-N, Schlette E, et al: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297, 2008
11. Cheson BD, Bennet JM, Grever M, et al: NCI Working Group Guidelines for CLL: Revised guidelines for the diagnosis and treatment. Blood 87:4990-4997, 1996
12. Amrein L, Hernandez T, Ferrario C, et al: Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 143:698-706, 2008
13. Jelinek D, Tschumper R, Geyer S, et al: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 115:854-861, 2001 (Pubitemid 34042903)
14. Fais F, Ghiotto F, Hashimoto S, et al: Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen recpetors. J Clin Invest 102:1515-1525, 1998 (Pubitemid 28492218)
15. Chng W, Schop R, Price-Troska T, et al: Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 108:2755-2763, 2006
16. Fleming T: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
17. O'Neill G, Stehn J, Gunning P: Tropomyosins as interpreters of the signalling environment to regulate the local cytoskeleton. Semin Cancer Biol 18:35-44, 2008 (Pubitemid 350266370)
18. Densham R, O'Neill E, Munro J, et al: MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21 Wafl/Cipl stability. Mol Cell Biol 29:6380-6390, 2009
19. Catovksy D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
20. Flinn I, Neuberg D, Grever M, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. J Clin Oncol 25:793-798, 2007 (Pubitemid 350002879)
21. Eichhorst B, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006 (Pubitemid 43156283)
22. Rai K, Peterson B, Appelbaum F, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
23. Knauf W, Lissichkov T, Aldaoud L, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009
24. Hillman P, Skotnicki A, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
25. Moutouh-de Parseval L, Weiss L, DeLap R, et al: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25:5047, 2007 (Pubitemid 350220451)
26. Xu Y, Li J, Ferguson GD, et al: Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114:338-345, 2009
27. Aue G, Njuguna N, Tian X, et al: Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 94:1266-1273, 2009
28. Casati C, Camisaschi C, Novellino L, et al: Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimuation signal for dendritic cell activation. J Immunol 180:3782-3788, 2008
29. Brignone C, Grygar C, Marcu M, et al: A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol 179:4202-4211, 2007
30. Baixeras E, Hard B, Miossec C, et al: Characterization of the lymphocyte activation gene 3-encoded protein: A new ligand for human leukocyte antigen class II antigens. J Exp Med 176:327-337, 1992
31. Workman C, Vignali D: The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 33:970-979, 2003 (Pubitemid 36546685)
32. Prigent P, El Mir S, Dreano M, et al: Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol 29:3867-3876, 1999
33. Brignone C, Escudier B, Grygar C, et al: A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15:6225-6231, 2009
34. Silverman R: Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virology 81:12720-12729, 2007